WPC C Hq}@$d8D԰&5D_ڵR-/f*KMܙP*#_.SAu#wdd'yd;ϻX9Z}諳 f =(,3SfG~.KZˋQoQ wJH5mx!|Nv ᳡LenJZ-9Y1V NN\Ňψ|xfΈ|l>g&e'O.bW jHsRWybݠd8g*jo˶% R9X8=C[ϊ E{k7u ń# اд8kU`8@KxeuLDA+];zm[dψ,0e0C^&Gv:4T r>o>/+Li}W/wKf'V35ک=TQJ=ݍuc\nM7## UN % 0:UNY^ w4 m 1u 72hhhhhhhhhhhhhhh 0mchp LaserJet 1300 PCL 5e,,,,0(9 Z6Times New Roman RegularX($USUS.,(9 Z 6Times New Roman RegularuH2 a1:i+003|xU3#37=CIQYag1.a.i.(1)(a)(i)1)a) i)(;3$2#  0  .3  0  1, 2, 3,Level 1Level 2Level 3Level 4Level 5 !USUS.,  _ X|XXXUnit13Objectives:InvestigationofaPositiveDATandImmuneHemolysis #X|XXX|@#  _X|XXX|_"3"  3$2#  1  .3  0    DescribethesignificanceofapositiveDirectAntiglobulinTest(DAT).3$Q݌(#(# Ќ  "3"  342#  2  .3  0    ListninepossiblecausesofapositiveDAT.34a݌t(#(# Ќ  "3"  3)2#  3  .3  0    StatethepurposeofthepretransfusionautocontrolorDAT.3)V݌`(#(# Ќ  "3"  3.2#  4  .3  0    StatethereasonwhyanEDTAtubeisthespecimenofchoicefortheDATandwhyfalse3.[݌L (#(# Ќ  0  positivereactionsmayoccurifaclottedbloodsampleisusedfortheDATtest.8 (#(# "3"  32#  5  .3  0    Listthepertinentpatienthistorywhichmustbeobtainedtoaidininterpretingthe $ t significanceofserologicaltesting.3݌ `(#(# Ќ  "3"  32#  6  .3  0    List4additionallaboratorytestsandexpectedresultswhich,alongwiththepatient's  L  clinicalcondition,willaidindiagnosingthepatient.3K݌ 8 (#(# Ќ  "3"  32#  7  .3  0    Listthecriteriawhichmustbemetforthedecisiontobemadenottoinvestigatea $  positiveDAT.3݌ (#(# Ќ  "3"  3 2#  8  .3  0    Listthespecimenstobecollectedwhenthedecisionismadetoinvestigatethepositive   DAT.3 ݌ (#(# Ќ  "3"  3 2#  9  .3  0    Statethethreebloodbankteststoperformwhichwillaidindeterminingthecauseofthe   positiveDAT.0 (#(#3 0 ݌p (# (# Ќ  "3 "  3\ 2#  10  .3  0    GivetheexpectedresultsfromthepreliminaryinvestigationofthepositiveDATthatwill3\ ݌\(#(# Ќ  0  determinethatnofurtherserologicaltestingneedstobedone.H(#(# "3 "  3 2#  11  .3  0    Define"immunehemolysis".0h(#(#3 ݌4h(#h(# Ќ  "3 "  32#  12  .3  0    Listthe7laboratorytestsandtheexpectedresultsthatwillaidinthediagnosisof3݌ p(#(# Ќ    immunehemolyticanemia.  \ "3 "  3;2#  13  .3  0    StatethemostcommonAutoImmuneHemolyticAnemia(AIHA)encounteredandthe H serologicalproblemsthisconditionmaycause.3;h݌4(#(# Ќ  "3 "  32#  14  .3  0    ForWarmAIHA(WAIHA)describetheexpectedserologicalresultsforthefollowing:   coatingprotein,antibodyclassinvolved,serumreactivity,eluatereactivity,and   specificityoftheantibody.3݌(#(# Ќ  "3"  3J2#  15  .3  0    ForWAIHAdescribetheprocedureusedtodetectalloantibodiesinthepresenceof  warmreactiveautoantibodies.3Jw݌(#(# Ќ  "3"  32#  16  .3  0    Definetheterm"leastincompatible".3݌l(#(# Ќ  "3"  32#  17  .3  0    DescribethespecialtransfusionconsiderationsforindividualswithWAIHA.3݌X (#(# Ќ  "3"  32#  18  .3  0    DescribethediseasesassociatedwiththeacuteandchronicformofColdAgglutinin D! Syndrome(CAS).  #X|XXX|#3݌0" (#(# Ќ  "3"  3 2#  19  .3  0    Describetheexpectedserologicalresultsforthefollowing:coatingprotein,serum #l! reactivity,eluatereactivity,specificityoftheantibodyandcoldagglutinintiter.3 :݌$X"(#(# Ќ  "3"  32#  20  .3  0    DescribethemechanisminvolvedinthecomplementcoatingofthepatientcellsinCAS.3݌$D #(#(# Ќ  "3"  32#  21  .3  0    Describethetwoprocedureswhichmaybeutilizedtodetectalloantibodiesinthe %0!$ presenceofcoldreactiveautoantibodies.3݌&"%(#(# Ќ  "3"  32#  22  .3  0    Describetheselectionofbloodandspecialtransfusionconsiderationsforpatientswith '#& CAS.3>݌(#'(#(# Ќ  "3"  3h2#  23  .3  0    DescribethemixedtypeAIHA.3h݌)$((#(# Ќ  "3"  3O2#  24  .3  0    Describetheexpectedserologicalresultsforthefollowing:coatingprotein,serum |*%) reactivity,eluatereactivity,specificityoftheantibodyandcoldagglutinintiter.3O|݌h+&*(#(# Ќ  "3"  32#  25  .3  0    DescribethetransfusionconsiderationsformixedtypeAIHA.3 ݌@-(,(#(# Ќ  "3"  3 2#  26  .3  0    DescribethedifferenceinpresentationofParoxysmalColdHemoglobinuria(PCH)in  childrenversusadults.3 !݌(#(# Ќ  "3"  3&"2#  27  .3  0    Describetheexpectedserologicalresultsforeachofthefollowing:coatingprotein,  antibodyclassinvolved,serumreactivity,eluatereactivity,specificityoftheantibodyand t coldagglutinintiter.3&"S"݌`(#(# Ќ  "3"  3#2#  28  .3  0    Describethemechanisminvolvedinthecoatingofthepatient'scellswithcomplementin L  PCH.3#$݌8 (#(# Ќ  "3"  3%2#  29  .3  0    DescribetheprocessforselectionofbloodforpatientswithPCH.3%K%݌$ t(#(# Ќ  "3"  3*&2#  30  .3  0    DescribetheserologicalcharacteristicsofmixedAIHAincluding:thecoatingprotein,  ` antibodyclassinvolved,serumtesting,eluatetestingandspecificityoftheautoantibody.3*&W&݌ L (#(# Ќ  "3"  3'2#  31  .3  0    Statetheteststoperformtodetermineifalloantibodyispresentwiththeautoantibodyin3''݌ 8 (#(# Ќ  0  patientswithmixedAIHA.$ (#(# "3"  3&)2#  32  .3  0    Describehowdrugsactlikehaptensininitiationofanimmuneresponsetothem.0 (#(#0@ (#(#0@ (#(#0@ p(#p(#0@ 0@ (#(#0@ ` (#` (#0@ (# (#0@ (#(#0@ h(#h(# @  @  @ 3&)S)݌  (# (# Ќ  "3 "  3,+2#  33  .3  0    Foreachofthefollowingbrieflydescribethemechanisminvolvedforinvivodrug3,+Y+݌ (#(# Ќ  0  sensitizationandthedrugmostcommonlyinvolved:DrugAdsorption(DA),Immune   ComplexAdsorption(IC),NonimmunologicProteinAdsorption,andInduction (#(#   ofAutoimmunity.   p "3!"  3`-2#  34  .3  0    ExplainwhysmallamountsofdrugmayresultinanacutehemolyticepisodeintheIC \ adsorptionmechanism.3`--݌H(#(# Ќ  "3""  3.2#  35  .3  0    NamethedrugwhichisthemostcommoncauseofadruginducedpositiveDAT.3..݌4(#(# Ќ  "3#"  3/2#  36  .3  0    Describetheserologicaltestingandexpected0p(#(#0p(#p(#  3//݌ p(#(# Ќ  0  resultsintheevaluationofthedruginduced0(#(#positiveDATforeachofthefollowing:0@!(#(#0@!(#(#0@!p(#p(#0@!(#(# \(#(# 0  DAT,serum,andtheuseofdrugcoated_cells._